August Bioservices, a contract development and manufacturing organization providing drug discovery, development, and manufacturing services, recently received an investment from Oak HC/FT and has appointed several industry executives to its leadership team, as the company to pursues strategic initiatives to grow the business.

August Bioservices provides testing capabilities for small and large molecules as well as clinical manufacturing services for vial filling, creams and ointments. Under the company’s new leadership team it will begin two major expansion projects. The company expand capacity and add new injectable filling platforms to its current Nashville facility. In addition, the company plans to build a new state-of-the-art testing and manufacturing facility.

These initiatives will allow August Bioservices to add large-scale lyophilization and sterile fill-finish capabilities to its existing clinical and commercial manufacturing offering.

“We are beyond excited to continue our momentum with our new branding, which we believe is an excellent representation of the way August Bioservices views our partnerships with our customers,” said Jenn Adams, CEO of August Bioservices. “We deploy multi-dimensional, integrated capabilities, flexible and scalable capacity, and unmatched scientific and manufacturing expertise to point the way forward from clinical testing to commercial success.”